Targeting of the purine biosynthesis host cell pathway enhances the activity of tenofovir against sensitive and drug-resistant HIV-1

Journal of Infectious Diseases

Volumn 208, Issue 12, 2013, Pages 2085-2094

  Heredia, Alonso ^a   Davis, Charles E ^a   Reitz, Marvin S ^a   Le, Nhut M ^a   Wainberg, Mark A ^b   Foulke, James S ^a   Wang, Lai Xi ^a   Redfield, Robert R ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Antiretrovirals; Drug resistance; HIV 1; NRTI; Resveratrol; Subtype C; Tenofovir

Indexed keywords

RESVERATROL; TENOFOVIR; ADENINE; CCR5 PROTEIN, HUMAN; CHEMOKINE RECEPTOR CCR5; PHOSPHONIC ACID DERIVATIVE; PURINE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STILBENE DERIVATIVE; DRUG DERIVATIVE;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPE B; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPE C; IN VITRO STUDY; NONHUMAN; PERIPHERAL LYMPHOCYTE; PHENOTYPE; PRIORITY JOURNAL; VIRUS CELL INTERACTION; ANALOGS AND DERIVATIVES; BIOSYNTHESIS; DRUG EFFECTS; HOST PATHOGEN INTERACTION; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; MONONUCLEAR CELL; VIRUS REPLICATION; ANTIRETROVIRALS; DRUG EFFECT; DRUG RESISTANCE; SUBTYPE C;

ADENINE; CELLS, CULTURED; DRUG RESISTANCE, VIRAL; DRUG SYNERGISM; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; LEUKOCYTES, MONONUCLEAR; ORGANOPHOSPHONATES; PURINES; RECEPTORS, CCR5; REVERSE TRANSCRIPTASE INHIBITORS; STILBENES; VIRUS REPLICATION;

ANTIRETROVIRALS; DRUG RESISTANCE; HIV-1; NRTI; RESVERATROL; SUBTYPE C; TENOFOVIR;

EID: 84894085804     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jit395     Document Type: Article

References (50)

1. World Health Organization. Global HIV/AIDS Response: Epidemic Update and Health Sector Progress Towards Universal Access. Geneva, Switzerland: HIV/AIDS Department, World Health Organization, 2011.
2. Amoroso A, Etienne-Mesubi M, Edozien A, et al. Treatment outcomes of recommended first-line antiretroviral regimens in resource-limited clinics. J Acquir Immune Defic Syndr 2012; 60:314-20.
3. Bartlett JA, Maro VA. Stavudine in first-line antiretroviral regimens in resource-limited settings: Time for a better solution. HIV Ther 2009; 3:109-11.
4. Lori F, Malykh A, Cara A, et al. Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science 1994; 266:801-5.
5. Palmer S, Shafer RW, Merigan TC. Hydroxyurea enhances the activities of didanosine, 9-[2-(phosphonylmethoxy)ethyl]adenine, and 9-[2- (phosphonylmethoxy)propyl] adenine against drug-susceptible and drug-resistant human immunodeficiency virus isolates. Antimicrob Agents Chemother 1999; 43:2046-50.
6. Wainberg MA, Miller MD, Quan Y, et al. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antivir Ther 1999; 4:87-94.
7. Clouser CL, Holtz CM, Mullett M, et al. Analysis of the ex vivo and in vivo antiretroviral activity of gemcitabine. PloS One 2011; 6:e15840.
8. Mayhew CN, Mampuru LJ, Chendil D, et al. Suppression of retrovirus- induced immunodeficiency disease (murine AIDS) by trimidox and didox: novel ribonucleotide reductase inhibitors with less bone marrow toxicity than hydroxyurea. Antiviral Res 2002; 56:167-81.
9. Fontecave M, Lepoivre M, Elleingand E, Gerez C, Guittet O. Resveratrol, a remarkable inhibitor of ribonucleotide reductase. FEBS Lett 1998; 421:277-9.
10. Horvath Z, Saiko P, Illmer C, et al. Synergistic action of resveratrol, an ingredient of wine, with Ara-C and tiazofurin in HL-60 human pro- myelocytic leukemia cells. Exp Hematol 2005; 33:329-35.
11. Ragione FD, Cucciolla V, Borriello A, et al. Resveratrol arrests the cell division cycle at S/G2 phase transition. Biochem Biophys Res Commun 1998; 250:53-8.
12. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: The in vivo evidence. Nat Rev Drug Discov 2006; 5:493-506.
13. Renaud S, de Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 1992; 339:1523-6.
14. Vang O, Ahmad N, Baile CA, et al. What is new for an old molecule? Systematic review and recommendations on the use of resveratrol. PLoS One 2011; 6:e19881.
15. Heredia A, Davis C, Redfield R. Synergistic inhibition of HIV-1 in activated and resting peripheral blood mononuclear cells, monocyte- derived macrophages, and selected drug-resistant isolates with nucleoside analogues combined with a natural product, resveratrol. J Acquir Immune Defic Syndr 2000; 25:246-55.
16. Wang LX, Heredia A, Song H, et al. Resveratrol glucuronides as the metabolites of resveratrol in humans: characterization, synthesis, and anti-HIV activity. J Pharm Sci 2004; 93:2448-57.
17. Clouser CL, Chauhan J, Bess MA, et al. Anti-HIV-1 activity of resveratrol derivatives and synergistic inhibition of HIV-1 by the combination of resveratrol and decitabine. Bioorg Med Chem Lett 2012; 22:6642-6.
18. Balzarini J, Pannecouque C, De Clercq E, et al. Antiretrovirus activity of a novel class of acyclic pyrimidine nucleoside phosphonates. Antimicrob Agents Chemother 2002; 46:2185-93.
19. Aquaro S, Svicher V, Ceccherini-Silberstein F, et al. Limited development and progression of resistance of HIV-1 to the nucleoside analogue reverse transcriptase inhibitor lamivudine in human primary macrophages. J Antimicrob Chemother 2005; 55:872-8.
20. Diamond TL, Roshal M, Jamburuthugoda VK, et al. Macrophage tropism of HIV-1 depends on efficient cellular dNTP utilization by reverse transcriptase. J Biol Chem 2004; 279:51545-53.
21. Brenner BG, Oliveira M, Doualla-Bell F, et al. HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS 2006; 20:9-13.
22. Loemba H, Brenner B, Parniak MA, et al. Co-receptor usage and HIV-1 intra-clade C polymorphisms in the protease and reverse transcriptase genes of HIV-1 isolates from Ethiopia and Botswana. Antivir Ther 2002; 7:141-8.
23. Delaugerre C, Roudiere L, Peytavin G, Rouzioux C, Viard JP, Chaix ML. Selection of a rare resistance profile in an HIV-1-infected patient exhibiting a failure to an antiretroviral regimen including tenofovir DF. J Clin Virol 2005; 32:241-4.
24. Deval J, White KL, Miller MD, et al. Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations. J Biol Chem 2004; 279:509-16.
25. Miller MD, Margot N, Lu B, et al. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. J Infect Dis 2004; 189:837-46.
26. Boyer PL, Sarafianos SG, Arnold E, Hughes SH. Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase. J Virol 2001; 75:4832-42.
27. Gu Z, Arts EJ, Parniak MA, Wainberg MA. Mutated K65R recombinant reverse transcriptase of human immunodeficiency virus type 1 shows diminished chain termination in the presence of 2', 3'-dideoxy- cytidine 5'-triphosphate and other drugs. Proc Natl Acad Sci U S A 1995; 92:2760-4.
28. Johnston E, Dupnik KM, Gonzales MJ, et al. Panel of prototypical infectious molecular HIV-1 clones containing multiple nucleoside reverse transcriptase inhibitor resistance mutations. AIDS 2005; 19:731-3.
29. Dore GJ, Cooper DA, Pozniak AL, et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients co- infected with HIV-1 and hepatitis B virus. J Infect Dis 2004; 189:1185-92.
30. Coutsinos D, Invernizzi CF, Xu H, et al. Template usage is responsible for the preferential acquisition of the K65R reverse transcriptase mutation in subtype C variants of human immunodeficiency virus type 1. J Virol 2009; 83:2029-33.
31. Hosseinipour MC, van Oosterhout JJ, Weigel R, et al. The public health approach to identify antiretroviral therapy failure: high- level nucleoside reverse transcriptase inhibitor resistance among Malawians Ming first-line antiretroviral therapy. AIDS 2009; 23: 1127-34.
32. Miller MD, Margot N, McColl D, Cheng AK. K65R development among subtype C HIV-1-infected patients in tenofovir DF clinical trials. AIDS 2007; 21:265-6.
33. Sunpath H, Wu B, Gordon M, et al. High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofo- vir-containing first-line regimen. AIDS 2012; 26:1679-84.
34. Frankel FA, Invernizzi CF, Oliveira M, Wainberg MA. Diminished efficiency of HIV-1 reverse transcriptase containing the K65R and M184V drug resistance mutations. AIDS 2007; 21:665-75.
35. Xu HT, Martinez-Cajas JL, Ntemgwa ML, et al. Effects of the K65R and K65R/M184V reverse transcriptase mutations in subtype C HIV on enzyme function and drug resistance. Retrovirology 2009; 6:14.
36. Gao RY, Mukhopadhyay P, Mohanraj R, et al. Resveratrol attenuates azidothymidine-induced cardiotoxicity by decreasing mitochondrial reactive oxygen species generation in human cardiomyocytes. Mol Med Report 2011; 4:151-5.
37. Touzet O, Philips A. Resveratrol protects against protease inhibitor- induced reactive oxygen species production, reticulum stress and lipid raft perturbation. AIDS 2010; 24:1437-47.
38. Billard C, Izard JC, Roman V, et al. Comparative antiproliferative and apoptotic effects of resveratrol, epsilon-viniferin and vine-shots derived polyphenols (vineatrols) on chronic B lymphocytic leukemia cells and normal human lymphocytes. Leuk Lymphoma 2002; 43:1991-2002.
39. Lu I, Ho CH, Ghai G, Chen KY. Resveratrol analog, 3, 4, 5, 4'-tetrahy- droxystilbene, differentially induces pro-apoptotic p53/Bax gene expression and inhibits the growth of transformed cells but not their normal counterparts. Carcinogenesis 2001; 22:321-8.
40. Robbins BL, Srinivas RV, Kim C, Bischofberger N, Fridland A. Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), bis(isopropyloxy- methylcarbonyl)PMPA. Antimicrob Agents Chemother 1998; 42: 612-7.
41. Miller MD. K65R, TAMs and tenofovir. AIDS Rev 2004; 6:22-33.
42. Kozal MJ, Chiarella J, John EP, et al. Prevalence of low-level HIV-1 variants with reverse transcriptase mutation K65R and the effect of antiretroviral drug exposure on variant levels. Antivir Ther 2011; 16:925-9.
43. Margot NA, Waters JM, Miller MD. In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine. Antimicrob Agents Chemother 2006; 50:4087-95.
44. Melikian GL, Rhee SY, Taylor J, et al. Standardized comparison of the relative impacts of HIV-1 reverse transcriptase (RT) mutations on nucleoside RT inhibitor susceptibility. Antimicrob Agents Chemother 2012; 56:2305-13.
45. Walle T, Hsieh F, De Legge MH, Oatis JE Jr, Walle UK. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 2004; 32:1377-82.
46. Patel KR, Brown VA, Jones DJ, et al. Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res 2010; 70:7392-9.
47. Marier JF, Vachon P, Gritsas A, Zhang J, Moreau JP, Ducharme MP. Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. J Pharmacol Exp Ther 2002; 302:369-73.
48. Shimoi K, Saka N, Nozawa R, et al. Deglucuronidation of a flavonoid, luteolin monoglucuronide, during inflammation. Drug Metab Dispos 2001; 29:1521-4.
49. Koide K, Osman S, Garner AL, et al. The use of 3, 5, 4'-tri- O-acetylresveratrol as a potential pro-drug for resveratrol protects mice from gamma-irradiation-induced death. ACS Med Chem Lett 2011; 2:270-4.
50. Kapetanovic IM, Muzzio M, Huang Z, Thompson TN, McCormick DL. Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats. Cancer Chemother Pharmacol 2010; 68:593-601.